Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

In the latest trading session, Merck (MRK) closed at $79.29, marking a +1.29% move from the previous day. The stock exceeded ...

Merck (MRK) ended the recent trading session at $78.27, demonstrating a +1.46% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for ...

Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...

Valuation and Upside Potential. Currently, MRK stock trades at around $80, valuing the company at 3.2 times its trailing revenues. This falls below its three-year average price-to-sales (P/S ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could be a steal of a deal.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...